NIH’s new Application Submission System & Interface for Submission Tracking (ASSIST) is available for the electronic preparation and submission of multi-project applications through Grants.gov to NIH. Applications to this FOA must be submitted electronically using ASSIST or an institutional system-to-system solution; paper applications will not be accepted.

It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information
Part 2. Full Text of the Announcement

Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information

Parkinson’s disease (PD) is a chronic, progressive movement disorder that affects the lives of at least 500,000 people across the United States, a figure that is expected to increase as our population ages. The average onset of characteristic motor symptoms, which are initially subtle and increasingly impact purposeful movement, occurs in the sixth decade of life; onset at much younger ages is also possible. Persons with PD also experience significant non-motor symptoms including changes in cognition and mood, sleep disturbances, and autonomic dysfunction. Currently available pharmacological and surgical treatments provide relief from some motor symptoms but fail to attenuate the ultimate progression of the disease. While significant research advances have been made, including the identification of environmental and genetic risk factors, a clear cause and a definitive cure for PD have remained elusive.

The NINDS Udall Centers of Excellence for Parkinson s Disease Research program was established in tandem with the Morris K. Udall Parkinson’s Disease Research Act of 1997 (P.L. 105-78), legislation to honor the distinguished Representative from Arizona who lived with PD. NINDS Udall Centers have since identified and characterized candidate and disease-associated genes, examined neurobiological and neuropathological mechanisms underlying PD, established improved PD models, developed and tested potential therapeutics, and explored novel avenues of clinical research. In 2018, there are nine Udall Centers across the United States.

The overarching goal of the NINDS Udall Centers of Excellence program is to establish a network of research Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for PD. Udall Centers pursue high-impact, synergistic research projects while serving as national leaders in PD research, and local resources for research career enhancement and outreach to the PD patient/advocacy community. Another important goal is to further advance PD research through broad sharing of data and research resources developed through this Centers program. The NINDS Udall Centers program prioritizes innovative and integrative research with significant potential for discovery. Udall Center applications are expected to identify and address an overall research theme that defines a critical challenge in PD research, emphasize novel ideas and approaches, as well as to utilize state-of-the-art technologies and a team-based approach to achieve stated goals. The overall theme of each Center, proposed research projects, and cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the identified PD research challenge.

Each applicant team may submit the combination of research projects (basic, translational, clinical) that best address the stated theme. Basic research has served and will continue to serve as the foundation of discovery in the Udall Centers program: applicants are encouraged to include basic research projects, as well as to continue to build upon this vital foundation with studies that translate basic and clinical research observations into improved treatments for PD. Inclusion of a translational research project is optional but encouraged; such projects should provide initial proof-of-concept that a proposed therapeutic agent has sufficient biological activity to warrant further development for the treatment of PD. Clinical research projects include patient-oriented research with a specific focus on understanding disease mechanisms. When formulating their applications, applicants are encouraged to consider the research recommendations resulting from the NINDS conference, "Parkinson's Disease 2014: Advancing Research Improving Lives."

The Specialized Center (P50) mechanism supports interdisciplinary, hypothesis-driven research activities. Programmatic requirements of this FOA include: three or more Research Projects, an Administrative Core, at least one integrated Research Core that is essential to and accelerates the progress of two or more Research Projects, a mission statement for and description of career enhancement of Center investigators, and a plan for periodic outreach activities to the local patient/advocacy community. If at least one Clinical Research Project is proposed, a corresponding Clinical Research Core must also be included within the application. Proposed studies must be feasible and justified within the budget limits described elsewhere in this announcement.

The following activities are nonresponsive to this FOA; applications containing any of these elements will not be reviewed:

• Pilot research projects.
• Clinical trials that address specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions.
• Research, discovery or method development Aims within Cores.
• Establishment and maintenance of institutional infrastructure and generalized resources (including brain banks, biospecimen repositories, databases and translational research facilities).

Responsive applications will demonstrate proven ability (renewals) or considerable potential (new applications) to: address critical challenges in PD research; contribute unique knowledge and scientific advances to the Udall Centers program; collaborate effectively with existing Centers; and serve as national leaders in PD research. Related, supportive factors include, but are not limited to, broad sharing of data and resources as appropriate and consistent with achieving the goals of the program. Udall Centers also serve as local resources for career enhancement activities for Center investigators, and meaningful outreach activities to the local PD community. Although new Centers are not expected to have pre-existing collaborations with established Centers, potential areas of shared interest with active NINDS Udall Centers should be considered and included in the application.

NINDS funding decisions will focus primarily on scientific merit, i.e., on those applications that are most likely to make innovative contributions to PD research and that demonstrate the potential to collaborate effectively across the Centers program. The NINDS will also consider the full scope of Udall Center programmatic activities when making funding decisions; applications proposing goals identical to or largely overlapping with active Udall Centers will receive lower program priority. In addition, the NINDS may also consider whether proposed research addresses recommendations from the NINDS conference "Parkinson's Disease 2014: Advancing Research, Improving Lives."

Per NOT-OD-16-011, the NIH expects applicants to apply rigor in designing and performing scientific research according to the NIH Principles and Guidelines for Reporting Preclinical Research.

See Section VIII. Other Information for award authorities and regulations.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Higher Education Institutions

• Public/State Controlled Institutions of Higher Education
• Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

o Hispanic-serving Institutions

o Historically Black Colleges and Universities (HBCUs)

o Tribally Controlled Colleges and Universities (TCCUs)

o Alaska Native and Native Hawaiian Serving Institutions

o Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

• Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
• Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

• Small Businesses
• For-Profit Organizations (Other than Small Businesses)

Governments

• State Governments
• County Governments
• City or Township Governments
• Special District Governments
• Indian/Native American Tribal Governments (Federally Recognized)
• Indian/Native American Tribal Governments (Other than Federally Recognized)
• Eligible Agencies of the Federal Government
• U.S. Territory or Possession

Other

• Independent School Districts
• Public Housing Authorities/Indian Housing Authorities
• Native American Tribal Organizations (other than Federally recognized tribal governments)
• Faith-based or Community-based Organizations
• Regional Organizations

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

• Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
• System for Award Management (SAM) (formerly CCR) Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
• o NATO Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
• eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
• Grants.gov Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

The Udall Center Director (PD/PI) must be an established leader in scientific research with a history of successful funding and proven expertise in the stewardship of large-scale research programs. Center Directors must lead the Administrative Core and may lead no more than one other component. Other qualifying factors include current research productivity, active research funding (NIH R01-equivalent or greater) and/or stewardship of multi-site clinical studies at time of submission, capacity for visionary leadership of an interdisciplinary team, and demonstrated experience in mentoring of junior faculty and trainees. Expertise in areas beyond PD research is encouraged if the Director’s skills can be applied in novel ways to advancement of knowledge of PD causes and progression, with the overall goal of advancing PD research into improved treatments and clinical practice. The PD/PI is expected to commit substantive effort to ensure success of the Udall Center.

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).

A button to access the online ASSIST system is available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

Most applicants will use NIH’s ASSIST system to prepare and submit applications through Grants.gov to NIH. Applications prepared and submitted using applicant systems capable of submitting electronic multi-project applications to Grants.gov will also be accepted.

It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

• Descriptive title of proposed activity
• Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
• Names of other key personnel
• Participating institution(s)
• Number and title of this funding opportunity

The letter of intent should be sent to:

Beth-Anne Sieber, PhD
Division of Neuroscience
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
Email: sieberb@ninds.nih.gov

Available Component Types	Research Strategy/Program Plan Page Limits
Overall	12
Admin Core	12
Core (use for research core and clinical core)	6
Project	12

Additional page limits described in the SF424 Application Guide and the Table of Page Limits must be followed.

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing a multi-component application.

The application should consist of the following components:

• Overall: required, maximum of 1
• Administrative Core: required, maximum of 1
• Research Core: required, minimum of 1
• Clinical Core: required for support of Research Project(s) proposing use of human subjects
• Projects: required, minimum of 3
• Research Project categories include: Basic, Translational and Clinical

When preparing your application in ASSIST, use Component Type Overall .

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

Complete entire form.

Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.

Follow standard instructions.

Other Attachments: The following information must be uploaded as individual attachments. The filename for each attachment is indicated below; filenames will be used to bookmark the attachments in the application image.

• Center Organizational Structure: provide a diagram demonstrating interactions among Center components.
• Udall Center Interactions: interactions among Udall Centers are an important component of the program. Therefore, applicants must provide a table as follows:
• Renewal Applications: provide a table to document interactions across current Udall Centers, emphasizing collaborative publications as well as sharing of resources and data consistent with achieving the goals of the program. Evidence of communication among Centers may be supported by invited seminars and hosted meetings among investigators from two or more Udall Centers.
• New Applications: provide a table that identifies potential (and any existing) collaborations with current Udall Centers
• Resource Availability and Sharing: Renewal Applications only
• Provide a table and brief description of resources developed in prior Udall Center project period(s), as well as specific examples of resource sharing within and beyond the Udall Centers program.
• Institutional PD Research: This attachment is required in order intended to provide overall context for proposed Udall Center efforts. List large-scale projects and institutional investments, including associated therapeutic development efforts, that support or complement PD research; define the potential (new applications) or ongoing (competing renewal applications) role of the Udall Center within this context. While it is not necessary for a new applicant institution to have established efforts in PD research, the attachment should detail any ongoing programs that could be leveraged and/or how the Udall Center will be supported as the foundation for institutional PD research. Examples include, but are not limited to
• Federal programs: NINDS Parkinson's Disease Biomarkers Program (PDBP); NIH Accelerating Medicines Partnership for PD (AMP PD); NIA Alzheimer's Disease Centers or other significant NINDS/NIA programs in Alzheimer's Disease-Related Dementias (ADRD); Department of Defense Congressionally Directed Medical Research Programs- Parkinson's Research Program (DoD CDMRP-PRP); NCATS Clinical and Translational Science Awards (CTSA).
• Non-Federal programs: Parkinson's Foundation (PF) Centers of Excellence; large-scale Michael J. Fox Foundation (MJFF) projects and/or consortia; and American Parkinson's Disease Association (APDA) Centers for Advanced Research.

Enter primary site only.

A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.

Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this FOA) for the entire application.

A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.

The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.

A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.

Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is required in the Overall component.

Specific Aims: Describe the overall aims of the proposed Udall Center

Research Strategy: The Overall section states the theme, vision and rationale for the proposed Udall Center, and provides an overview of planned synergistic activities. Organize the Research Strategy into sections on Significance, Innovation and Approach.

Significance: State the overall theme and define the critical PD research challenge(s) to be addressed in the proposed Udall Center. Provide a vision statement for the Center, including justification for the stated theme, scientific premise, and expected contributions to the advancement of PD research and treatment. Include the overall Udall Center program objectives and related implementation plan for the proposed grant period. Justify the proposed interdisciplinary approach and the use of the specialized Center mechanism (P50), including the potential contribution (new application) or proven capacity (renewal application) as a national leader in and local resource for PD research; related justification may include, but is not limited to, broad sharing of data and research resources as appropriate and consistent with achieving the goals of the program.

Innovation: Describe how novel approaches, investigator expertise, and collaborative activities will advance the goals of the Udall Centers program, including unique contributions that will elucidate the causes of and result in therapeutic advances for PD.

Approach: Describe the general research framework of the Center. Discuss the proposed research program, highlighting its central theme. Describe the synergy among the Center components, including the Administrative and Research/Clinical Core(s), focusing on the scientific and collaborative approaches that will ensure thematic coherence of Center research and activities. Detailed descriptions of preliminary data for new projects (new and renewal applications) and/or progress on existing projects (renewal applications) should be included within the relevant Research Project section, not in the Overview. If foreign components are included, describe how those present special opportunities for furthering research programs through unusual talent, resources, populations, or environmental conditions that exist in other countries and are not readily available in the United States (US) or that augment existing US resources.

New and renewal applications should include the following information, respectively:

New applications: Provide summary evidence for feasibility, including preliminary findings, that support the formation of a Udall Center of Excellence. Present compelling evidence that the assembled research team will work together effectively to accomplish the goals of the proposed Center and advance research in PD. Detail institutional support for a strong research base on PD and/or other neurodegenerative disorders that may be leveraged to build the Udall Center. Describe potential to serve as a national leader in and local resource for PD research. Outline plans for effective sharing of research resources and data with the scientific community.

Renewal applications: Provide a brief synopsis of the overall accomplishments of the Udall Center during the prior funding period, including the overall scientific/clinical merit and impact of projects/cores and of the Udall Center as a synergistic whole. Provide examples of Center leadership in the advancement of PD research, at an institutional and national level. Provide examples of effective outreach to the local community. Describe Udall Center contributions to ongoing institutional research on PD and related disorders. Highlight collaborative interactions among the Center investigators; continuation of prior and establishment of new collaborations within the Udall Centers network; and the effectiveness of the core resources and facilities for collaborations within and beyond the Center.

Letters of Support:

Institutional Commitment (required): Include a letter from a high-level institution official(s) (e.g., Dean of the School of Medicine, Vice President for Research) to confirm institutional commitment to current (renewal application) or proposed (new application) Centers. The letter should provide details regarding:

• Establishment (for new applications) or sustainment (for renewal applications) of institutional commitment to the NINDS Udall Center of Excellence. Examples of institutional commitment may include but are not limited to: funding for pilot projects; support for recruitment of scientific talent and career enhancement activities, such as support for a designated Udall Research Fellow; provision of discretionary resources to the Udall Center Director; access to institutional infrastructure; assignment of specialized research space; funding and resources for community outreach activities; and/or other means of support.
• Institutional promotion and maintenance of overall scientific excellence in PD research, including prioritization and integration of the Udall Center into institutional efforts. Udall Centers are encouraged to leverage additional institutional partnership opportunities to further program goals.
• The role of the institutional official in conflict arbitration and resolution, should such arise among Udall Center investigators.
• For applicant institutions receiving funding for other, significant PD-relevant research projects from Federal or Non-Federal entities: describe the unique contributions of the Udall Center to the institutional PD research effort, how interactions among institutional PD-relevant projects will advance PD research and explicate institutional commitment to the support of the Udall Center program in this overall context. Such projects include but are not limited to:
• Federal programs: NINDS Parkinson's Disease Biomarkers Program (PDBP); NIH Accelerating Medicines Partnership for PD (AMP PD); NIA Alzheimer's Disease Centers or other significant NINDS/NIA programs in Alzheimer's Disease-Related Dementias (ADRD); Department of Defense Congressionally Directed Medical Research Programs- Parkinson's Research Program (DoD CDMRP-PRP); NCATS Clinical and Translational Science Awards (CTSA).
• Non-Federal programs: Parkinson's Foundation (PF) Centers of Excellence; large-scale Michael J. Fox Foundation (MJFF) projects and/or consortia; and American Parkinson's Disease Association (APDA) Centers for Advanced Research.

Collaboration with Nongovernmental Organizations (if applicable): Udall Centers and nongovernmental research, philanthropic and patient advocacy organizations pursue common goals to understand causes of and improve treatments for PD. Include letters from nongovernmental organizations that detail planned and/or ongoing partnerships with these groups, including support for complementary research activities as well as collaboration on planned Center community outreach efforts such as the annual symposium.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

As Centers of Excellence, Udall Centers are expected to share data, resources and knowledge broadly with the research community. Applicants are expected to detail how this component will:

• Expedite timely transfer of information to appropriate, broadly shared databases, including the NINDS Data Management Resource (DMR) or other designated NINDS database, to fulfill data sharing goals as appropriate. Deposition of data solely into an institutional database, whether at the applicant or at a collaborator's institution, may not be considered consistent with achieving the program goals.
• Implement standardized collection and deposition of biospecimens into the designated NINDS biorepository, the Biospecimen Exchange for Neurological Disorders, BioSEND.
• Facilitate sharing of knowledge, data, research resources and biospecimens with other Udall Centers and the PD research community as appropriate and consistent with achieving the goals of the program.

Appendix:

Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Overall)

When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, there must be at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record within the application. The study record(s) must be included in the component(s) where the work is being done, unless the same study spans multiple components. To avoid the creation of duplicate study records, a single study record with sufficient information for all involved components must be included in the Overall component when the same study spans multiple components.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed

Delayed Onset Study

All instructions in the SF424 (R&R) Application Guide must be followed

All instructions in the SF424 (R&R) Application Guide must be followed.

When preparing your application, use Component Type Admin Core .

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

Complete only the following fields:

• Applicant Information
• Type of Applicant (optional)
• Descriptive Title of Applicant’s Project
• Proposed Project Start/Ending Dates

Enter Human Embryonic Stem Cells in each relevant component.

Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.

Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

Facilities and Other Resources: As part of the description of the institutional environment, applicants must provide a description of Center career enhancement activities. These activities must address the goals of the Udall Centers program by fostering investigator proficiency across the broad spectrum of basic, translational and clinical concepts necessary for investigators to successfully and independently navigate critical issues in PD research.

Capitalizing on the unique interdisciplinary teams within Udall Centers, planned activities will provide opportunities for non-clinician scientists to gain understanding of and exposure to the clinical aspects of PD research, such that basic research is approached as it relates to the clinical manifestation of the disease. Conversely, clinician scientists will gain exposure to and understanding of the basic science that contributes to discovery of disease mechanisms and therapeutic targets.

Career enhancement activities organized by the Udall Center must be above and beyond institutional training programs and focused on activities that advance investigator skills and knowledge across the interdisciplinary Center program. Provide information on the following:

• Mission statement for Center-specific career enhancement activities.
• Brief overview of planned activities over the five-year period.
• Strategy for cross-training of basic and clinical Center researchers.
• Complementarity to and collaborations with existing institutional programs.
• Evidence of career enhancement activities accomplished during the prior funding period (renewal application) or plans for local leadership in career enhancement activities for Center investigators (new application).

Other Attachments: Provide the following attachments with the filenames indicated below; filenames will be used to bookmark the attachment in the application image.

Community Outreach Activities: The Administrative Core will serve as the point of information for the public, and as a resource for the local patient/caregiver community. Outreach activities must be specific to the Udall Center, and thus will be designed to inform and engage the public about ongoing Center research approaches, as well as how Center findings relate to current advances in PD research and treatment. Active participation of patient advocacy groups in the planning and conduct of outreach activities is encouraged. Provide a description of planned outreach to the local and national PD patient community, including:

• Plans for an annual symposium to present Udall Center research results to the local patient community.

o Important: the primary goal of the Udall symposium is dissemination of Center research activities; it may not be designed solely as a general information update on PD research and treatment, which is often covered by other institutional programs.

o The Center symposium may occur in tandem with a general informational program but must clearly include a dedicated update on recent Center research and its relevance to patient interests.

o Renewal applications: include agenda from recent Udall Center symposia.

• Involvement of Center investigators in outreach activities.
• Innovative means through which the Center will relay research advances to the lay community.
• Dissemination of results to research study participants.
• Broad outreach efforts including Center website, social media approaches.
• Partnership with nongovernmental PD organizations, including patient advocacy groups, research organizations and philanthropic foundations.
• Inclusion of a patient advocate on the Udall Center External Advisory Committee (EAC). To avoid potential conflict of interest, candidates currently participating in a clinical trial at the Center and/or associated medical center should not serve on the Udall Center EAC.
• A lay language summary of Udall Center goals and research activities.
• Provide evidence of (renewal application) or plans for (new application) effective outreach to the local patient/advocacy community.
• The following activities are beyond the scope of community outreach as defined by this FOA:
• General symposia on PD research and treatment
• - Updates on Udall Center research and its relevance to the patient/caregiver community must be included in any proposed symposium.
• Continuing Medical Education (CME) programs for health care professionals

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

• In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Core Lead and provide a valid eRA Commons ID in the Credential field.
• In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
• Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
• If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
• The Center Director (PD/PI) must lead the Administrative Core.
• An Associate Center Director may be named, who will assist the Center Director with oversight of administrative and scientific efforts of the Center.
• A Center Administrator must be named.

o The Administrator must be familiar with NIH grants policies and business practices and provide expert consultation in matters of fiscal administration.

o Research investigators cannot serve as the Center Administrator.

Budget forms appropriate for the specific component will be included in the application package.

Effort of Administrative Core personnel must be commensurate with the time required for effective performance of duties.

Budget for the following Udall Center-specific activities should be included in the Administrative Core:

• Annual NINDS Udall Centers Meeting: Include travel and lodging costs for the Center Director, Center Administrator, and Project and Core Leads to attend the annual meeting.
• External Advisory Committee (EAC): Include all EAC-related costs (meeting and travel) in the proposed budget. To promote efficient spending, budgeted costs for EAC member travel will be within range of local per diem rates (as per General Services Administration (GSA) guidance) and follow general NIH guidelines for travel and expense reimbursement rates.
• Udall Center Website: Include all costs for the development (new applications) or maintenance (renewal applications) of the Center Website. Related costs for development of effective Center-based social media outreach strategies may also be included.
• Community Outreach Activities: Include funds for an annual symposium at which Udall Center investigators speak to the local patient community about research ongoing at the Center, as well as funds for other planned Center outreach activities. Budget should be dedicated to presentation of Udall Center activities, rather than for general departmental or institutional outreach. General outreach activities by Udall Center investigators may also be described to provide context.
• Career Enhancement Activities: Include funds for general career enhancement activities for Center trainees and investigators. Administrative Core funds may not be budgeted for ongoing institutional programs or for support of individual trainees or investigators; associated costs for the latter should be included in the Research Project(s) or Core(s) in which the trainees/investigators participate.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

Specific Aims: Describe the goals and planned activities of the Administrative Core

Research Strategy: Organize the Research Strategy into sections on Significance, Innovation and Approach:

Significance: Describe how the Administrative Core will serve as the organizational foundation for research activities of the Center, as well as how the Core will effectively support Center service as 1) a national leader in and local resource for PD research; 2) a pro-active source for career enhancement of Udall Center trainees and investigators; and 3) an effective organizer of periodic, Udall Center-specific outreach activities for the local PD patient/advocacy community.

Innovation: Describe novel approaches utilized by the Administrative Core to maximize synergy among Udall investigators and foster productive relationships with the broader research and patient/advocacy communities.

Approach: Describe the proposed activities of the Core, including but not limited to the following roles:

• Promote the integration and function of Center components and activities.
• Provide support for the Center Director in oversight of Center governance.
• Schedule regular meetings of the Center Executive Committee.
• Organize timely meetings of the Center External Advisory Committee (EAC).
• Develop and execute periodic community outreach efforts, including an annual symposium for local PD patients/advocates that focuses specifically on presentation of Udall Center activities and results.
• Coordinate career enhancement activities within the Center.
• Design common protocols and outcome adjudication processes.
• Standardize biospecimen and data collection practices.
• Expedite timely transfer of biospecimens to the NINDS BioSEND repository.
• Facilitate timely entry of clinical data into the NINDS Data Management Resource or other NINDS-designated data repository.
• Maintain an accounting of resource generation and related utilization, and steps taken to maximize the research utilization of these resources within and beyond the Udall Center.
• Provide advance notice of manuscripts and embargoed publications to the NINDS program official; work with the NINDS Office of Communications and Public Liaison on press releases and social media outreach highlighting Center accomplishments.
• Prepare and submit annual progress reports.
• Provide assurance of compliance with NIH policy requirements.
• Establish and maintain the Center's website, as well as any proposed social media presence.
• Coordinate Center participation in the annual Udall Center Directors' meeting.
• Renewal applications should also describe the accomplishments of the Administrative Core during the prior funding period.

The Approach section should also include plans for the following:

• Administrative Structure: Describe the administrative structure of the Udall Center, including decision-making processes and lines of communication; if applicable, relay detailed plans to foster effective communication among investigators at distinct geographic/institutional sites. Detail the administrative, technical, and scientific responsibilities for Center personnel and collaborators.
• Center Governance: Describe plans to convene (new application) or continue (renewal application) an internal Executive Committee, consisting of the Center Director, Associate Director (if applicable), Center Administrator, Project Leaders and Core Leaders, to assist the Director with scientific and administrative decisions. Describe Executive Committee activities, including regular meetings to discuss Center activities and direction. Outline inclusion of institutional officials. Include conflict resolution strategy.
• External Advisory Committee (EAC): Describe plans for the EAC, to be composed of at least five outside experts convened to provide unbiased scientific and programmatic evaluation. Committees will include some members from outside the Udall Centers program. Ideally, EAC scientific expertise will complement current projects as well as anticipated future directions of the Center. A patient advocate, preferably from the local/regional community, must also be included on the EAC to provide important perspective; to avoid potential conflict of interest, however, patients or caregivers participating in clinical trials at the Center and/or associated medical centers should not participate. While annual meetings may not be feasible, it is strongly recommended that Center Directors hold in-person EAC meetings early, mid-way and toward the end of the project period, to obtain timely external assessments of Center progress and recommendations for future direction. The program officer will attend EAC meetings as an observer and resource for NIH programs and policies. Regular EAC updates and evaluations are to be forwarded to the program officer and included in noncompeting continuation reports during EAC meeting years.

o New Centers: describe the anticipated expertise required on the EAC, but do not name or include letters from potential EAC members.

o Renewal Centers: describe the activities and influence of the EAC during the prior budget period. Provide names of continuing EAC members; if membership will change upon renewal, provide areas of expertise (but not specific members) to be added.

• Center Website: Include plans for establishing (new application) and maintaining (renewal application) a Center website; plans for constructing and/or updating this website should also be included. Because the Udall Centers serve as the nexus of NINDS-funded Parkinson’s disease research, members of the research community, advocacy organizations, people with PD and the general public have considerable interest in remaining informed on research progress at each Center. The website should contain a list of research resources as well as a prominently placed, brief (1 paragraph) statement on Public Health Relevance, which describes the goals and recent discoveries of the Center in plain language. This summary should also relay recent Center contributions to understanding the etiology and pathogenesis of PD, as well as how ongoing research will lead to the development of new treatments. Updates should be sufficiently frequent to reflect recent discoveries. The NINDS Udall Centers website provides links to all active Centers.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

Appendix:

Limited items are allowed in the Appendix.Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Administration Core)

When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed

Delayed Onset Study

All instructions in the SF424 (R&R) Application Guide must be followed

When preparing your application, use Component Type Core.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

Complete only the following fields:

• Applicant Information
• Type of Applicant (optional)
• Descriptive Title of Applicant’s Project
• Proposed Project Start/Ending Dates

Enter Human Embryonic Stem Cells in each relevant component.

Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.

Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

• In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Core Lead and provide a valid eRA Commons ID in the Credential field.
• In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
• Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
• If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
• The Research Core Lead must have appropriate expertise, as well as a record of productivity and collaboration, to ensure success of the Core. The expertise of the Core Lead may focus in areas other than PD research if relevant skills can be readily applied to the achievement of Center goals.

Budget forms appropriate for the specific component will be included in the application package.

Effort of the Research Core Lead and Core personnel must be commensurate with the time required for effective performance of proposed duties.

The following parameters apply to Research Core budgets:

• Funds for collection of biospecimens and/or postmortem tissues from Udall Center cohort subjects and for direct use in Udall Center Research Projects should be included within the Clinical Core budget.
• Budget for biospecimen collection should be based upon estimates received from the NINDS BioSEND repository, as well as dedication of sufficient personnel effort for timely transfer of samples.
• Budget for collection and transfer of clinical data to the NINDS Data Management Resource (DMR) should be included within the Clinical Core budget.
• Funds to establish or support institutional or general infrastructure (e.g. databases; biospecimen banking efforts, including postmortem tissues) beyond the immediate scope of Udall Center research activities are not permitted in a Udall Center Research Core. For NINDS policy on support for general banking of postmortem tissue, see: Notice of Change in Funding Mechanism for Brain Banks.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

Specific Aims: Describe the goals and planned activities of the Research Core, as well as the specific means by which it will directly address the overarching theme of the proposed Udall Center. Specify the Projects that the Core will support.

Research Strategy: Organize the Research Strategy into sections on Significance, Innovation and Approach.

Significance: Describe the essential relationship of the Research Core to at least two proposed Research Projects, the means through which this Core will advance the aims of each associated project, and what resources will be generated and shared, and how the Core will support the Center's status as a local resource for and national leader in PD research.

Innovation: Describe how the standardized approaches and facilities utilized will both address the theme of the Udall Center and advance PD research.

Approach: Indicate percent usage by proposed Research Projects. For renewal applications, if continuation of a previously awarded Core is proposed, major accomplishments during the prior funding period must be described, including how resources generated in Research Cores are shared within and optimally beyond the Udall Center as appropriate.

Research Core approaches may include, but are not limited to:

• Shared, standardized assays.
• Standardized animal models.
• Omics-based approaches (e.g. genomics, metabolomics, proteomics, transcriptomics).
• Statistics and data management.
• Neuropathology.

o Support for human subjects-based neuropathology is limited to enrolled Udall cohort subjects only, i.e. those subjects participating in Udall Center clinical research projects (see below).

Research Core approaches cannot include the following:

• Hypothesis- or discovery-driven Aims.
• Method or tool development.
• Brain or tissue banking (i) from subjects not enrolled in the Udall cohort and (ii) beyond that specifically required for Udall Center research projects.

Establishment and maintenance of institutional infrastructure and generalized resources (including brain banks, biospecimen repositories and databases); such activities are beyond the scope of this FOA and other funding mechanisms should be utilized for those purposes

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

• All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

As Centers of Excellence, Udall Centers are expected to share data, resources and knowledge broadly with the research community. Applicants are expected to detail how this component will:

• Expedite timely transfer of information to appropriate, broadly shared databases, including the NINDS Data Management Resource (DMR) or other designated NINDS database, to fulfill data sharing goals as appropriate. Deposition of data solely into an institutional database, whether at the applicant or at a collaborator's institution, may not be considered consistent with achieving the program goals.
• Implement standardized collection and deposition of biospecimens into the designated NINDS biorepository, the Biospecimen Exchange for Neurological Disorders, BioSEND.
• Facilitate sharing of knowledge, data, research resources and biospecimens with other Udall Centers and the PD research community as appropriate and consistent with achieving the goals of the program.

Appendix:

Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Research Core)

When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed

Delayed Onset Study

All instructions in the SF424 (R&R) Application Guide must be followed

When preparing your application, use Component Type Core.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

Complete only the following fields:

• Applicant Information
• Type of Applicant (optional)
• Descriptive Title of Applicant’s Project
• Proposed Project Start/Ending Dates

Enter Human Embryonic Stem Cells in each relevant component.

Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.

Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

• In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Core Lead and provide a valid eRA Commons ID in the Credential field.
• In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
• Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
• If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
• The Clinical Core Lead must have appropriate expertise, as well as a record of productivity and collaboration, to ensure success of the Core. The expertise of the Core Lead may be in areas outside of PD research if relevant skills can be readily applied to achievement of Center goals.
• The Clinical Core must include personnel who will ensure and facilitate data quality, transfer, sharing, and biological specimen submission to the NINDS Data Management Resource (DMR) and NINDS BioSEND repository, respectively.
• Effort of Clinical Core Lead and personnel must be commensurate with the time required for effective performance of proposed duties.

Budget forms appropriate for the specific component will be included in the application package.

Clinical Core funds must be dedicated solely to those clinical research activities necessary to support Udall Center Research Project(s).

Regarding support of for clinical cohorts, funds should be budgeted only for subjects who are directly involved in Udall Center research projects.

Funds cannot be requested or used to follow extended cohorts or populations, or to collect data and biospecimens beyond those required for research activities of the proposed Center.

Specific requirements for Clinical Core budget are as follows:

• Biospecimen collection and banking: The NINDS requires standardized human biospecimen collection protocols and banking at the designated NINDS repository, BioSpecimen Exchange for Neurological Disorders (BioSEND). All studies collecting biospecimens must submit these samples as well as associated clinical data (below). NINDS policy requires inclusion of associated costs within application budgets. Investigators are therefore strongly encouraged to contact the following repositories for updated pricing and policies early in the application process, and to include related costs in the Clinical Core budget.

o BioSEND: see the "Request a Quote" page for banking of DNA, RNA, biofluids (blood, serum, plasma, CSF, urine, saliva) and other biospecimens.

o NINDS Human Cell and Data Repository: contact NINDS@dls.rutgers.edu to obtain quotes for: banking of peripheral blood mononuclear cells (PBMC) and/or fibroblasts, iPSC generation and genome editing.

• Clinical data standardization and database entry: To harmonize data and foster sharing across PD cohorts, within and beyond the Udall Centers program, the NINDS expects standardized collection of clinical data from Udall Centers. Data are to be collected at least annually for longitudinal Udall Center cohorts, and at baseline (at the least) for familial and genetic cohorts/studies.

o All Udall Center clinical data must be collected using the Protocol and Forms Research Management (ProFoRMS) module of the NINDS Data Management Resource (DMR), unless otherwise directed by the Udall Center program officer. Applicants must include sufficient, dedicated budget to support timely transfer of data into the DMR or other designated NINDS database.

• Subject recruitment and retention: Include dedicated budget to support proactive subject recruitment and retention. Recruitment of subjects from diverse populations is an essential element of Udall Center clinical research; allocation of funds for periodic, targeted community outreach programs to increase diversity in Udall Center subject cohorts is strongly encouraged.

All related costs must be anticipated, budgeted and justified by the applicant; the NINDS will not provide supplemental funds to cover costs for required biospecimen and data collection activities.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

Specific Aims: Provide details regarding the subject population to be enrolled, related clinical data and biospecimens to be collected, as well as the specific means by which the Clinical Core will directly address the overarching theme of the proposed Udall Center.

Research Strategy: Organize the Research Strategy into sections on: Significance, Innovation and Approach.

Significance: Describe contributions of the Clinical Core to the goals of the Udall Center and its essential relationship to the complementary Clinical Research Project(s). Justify the importance of the patient cohort, and related research, to the goals of the Udall Center program and to the advancement of PD research.

Innovation: Describe how the activities of the Clinical Core, including novel approaches to recruitment and pro-active enhancement of diversity, will address the theme of the Udall Center and advance PD research.

Approach: Describe the proposed activities of the Clinical Core which may include, but are not limited to, the following:

• Recruit, enroll and follow a defined cohort of patients and control subjects to be studied specifically in Udall Center research projects. Detailed justification for the cohort, including its size and its direct connection to proposed Udall Center studies, must be provided.

o Renewal applications should provide historical information on the Udall Center cohort(s), and justify the need to continue following and/or increase enrollment in prior cohorts.

• Utilize and demonstrate compliance with NINDS Parkinson's Disease Biomarkers Program (PDBP) biospecimen collection procedures and required clinical assessment forms.

o If longitudinal analysis of the Udall cohort is planned, clinical assessments as defined by the PDBP visit schedule must be performed every 12 months, at a minimum.

o If family and/or genetic studies are proposed, baseline clinical assessments (at the least) are required.

o If specific biospecimens or data cannot be collected, please contact the NINDS Udall Centers program officer to discuss alternatives.

• Timely entry of standardized clinical data in the NINDS Data Management Resource (DMR), using the Protocol and Forms Research Management System (ProFORMS) module.
• Standardize collection, submission, and storage of approved biospecimens according to the NINDS Parkinson's Disease Biomarkers Program (PDBP) protocols.
• Deposit approved biospecimens in the designated NINDS repository, including the NINDS Human Biospecimen and Data Repository (BioSpecimen Exchange for Neurological Disorders, BioSEND) and the NINDS Human Cell and Data Repository.
• Provide information and samples to other Centers and researchers as requested. Promote patient education and community outreach, in collaboration with the Administrative Core.
• Integrate new technologies (e.g. mobile technologies, wearable devices, telemedicine) to improve data collection and subject participation.

Inclusion of large cohorts followed for general or institutional PD research is not responsive to this FOA: cohort recruitment, enrollment and follow-up must be justified by the Aims of proposed Udall Center projects. If a proposed (new application) or established (competing renewal) cohort is being followed to autopsy, provide the precise number of subjects supported through Udall Centers studies.

Applicants are strongly encouraged to establish relationships with PD patient and advocacy groups and solicit their input on recruitment and the clinical meaningfulness of the question under study.

Every effort should be made to serve diverse racial and ethnic populations with this Core, especially in areas where those populations represent a significant proportion of the local demographic.

Recruitment and retention plans, including a discussion of the availability of subjects for the proposed study and the ability of enrolling centers to recruit and retain the proposed number of subjects, including women and minorities, should be included. Recruitment and retention strategies should be tailored and targeted for specific populations as appropriate. Strategies should be proven and/or creative/innovative. Data supporting recruitment and retention estimates should be provided. For multi-site studies, a site activation and management plan should be included. Study timeline, including enrollment period, and completion stage, should be described.

Collection of biospecimens and clinical data will follow policies and procedures of the NINDS Parkinson's Disease Biomarker Program (PDBP). A Global Unique Identifier (GUID), assigned by the NINDS Data Management Resource (DMR), is required for each enrolled participant. Clinical assessments will include core PDBP clinical elements and will occur at least annually for longitudinal cohorts and at least at baseline for familial cohorts and genetic studies. Collection of clinical assessments beyond the PDBP core assessment should be coordinated with the NINDS. All clinical data will be entered through the Protocol and Forms Research Management (ProFoRMS) module of the PDBP DMR, unless otherwise directed by the NINDS program officer. Subject consent is expected to allow for broad data sharing with both industry and academic investigators through the NINDS PDBP DMR, as appropriate and consistent with achieving the goals of this program.

Letters of Support:

• BioSEND repository: Include a quote for banking of biospecimens in the BioSEND repository. Information provided in the quote should match plans for subject enrollment as well as research plans for related projects. Information is available through the BioSEND "Request a Quote" website.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

• All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

As Centers of Excellence, Udall Centers are expected to share data, resources and knowledge broadly with the research community. Applicants are expected to detail how this component will:

• Expedite timely transfer of information to appropriate, broadly shared databases, including the NINDS Data Management Resource (DMR) or other designated NINDS database, to fulfill data sharing goals as appropriate. Deposition of data solely into an institutional database, whether at the applicant or at a collaborator's institution, may not be considered consistent with achieving the program goals.
• Implement standardized collection and deposition of biospecimens into the designated NINDS biorepository, the Biospecimen Exchange for Neurological Disorders, BioSEND.

Facilitate sharing of knowledge, data, research resources and biospecimens with other Udall Centers and the PD research community as appropriate and consistent with achieving the goals of the program.

Appendix:

Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Clinical Core)

When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

All instructions in the SF424 (R&R) Application Guide must be followed.

When preparing your application, use Component Type Project.'

Basic research projects are hypothesis-driven investigations designed to elucidate disease mechanisms and identify optimal targets for therapeutic intervention. Basic research may utilize model systems or de-identified human biospecimens (see below). While serving as the basis for discovery, this research should be informed and refined by the results of well-designed clinical studies on PD.

For purposes of this FOA, and according to NIH policy, in vitro studies that utilize de-identified human biospecimens (i.e. those falling under 45 CFR part 46.101(b) (4) (Exemption 4)) should be proposed as basic research projects.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

Complete only the following fields:

• Applicant Information
• Type of Applicant (optional)
• Descriptive Title of Applicant’s Project
• Proposed Project Start/Ending Dates

Enter Human Embryonic Stem Cells in each relevant component.

Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.

Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

• In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Project Lead and provide a valid eRA Commons ID in the Credential field.
• In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
• Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
• If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
• The Basic Research Project Lead must demonstrate excellent scientific productivity and significant potential to advance PD research over the five-year project period. In addition, project leadership requires active, R01-equivalent, independent funding at the time of application submission. The expertise of Project Lead may be in areas outside of PD research if relevant skills can be readily applied to achievement of Center goals.
• Effort of Basic Research Project Lead and personnel must be commensurate with the time required for effective performance of proposed duties.

Budget forms appropriate for the specific component will be included in the application package.

Induced pluripotent stem cell (IPSC) line development: projects proposing to develop iPSC lines should include budget for costs related to support from the NINDS Human Cell and Data Repository (NHCDR)

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

Specific Aims: State the aims of the basic research project and the hypotheses to be tested. Justify need for the Udall Center structure to accomplish the proposed aims.

Research Strategy: Organize the Research Strategy into sections on Significance, Innovation and Approach.

Significance: Describe and justify the identified basic research need in the context of the critical PD research challenge identified by the Center theme. Describe the contributions of the basic research project to the goals of the Udall Center. Detail how successful completion of the proposed studies will inform and advance PD research and treatment, especially the crucial challenge identified by the Center theme. State the biological rationale for the intended approach, including supporting data from rigorously designed experiments.

Innovation: Provide evidence that use of novel concepts, models, and/or techniques will contribute to the advancement of PD research.

Approach: Describe the experimental approaches and model system(s) utilized to address the specific aims. Examples of basic research projects include, but are not limited to, the following:

• Characterization of cellular and molecular mechanisms of disease processes.
• Elucidation of the mechanism of action, including neural pathways and systems contexts, of identified PD risk genes.
• Identification and characterization of genetic and/or environmental risk factors that predict disease onset and progression.
• Identification of novel therapeutic targets and pathways via hypothesis-driven, mechanistic studies.
• Development of improved animal models, and their use for investigation of disease pathophysiology, progression and efficacy of therapeutic intervention.
• Research in model systems designed to validate clinically identified biomarkers for disease onset, progression, and response to treatment.
• Use of de-identified human biospecimens, including postmortem tissues and other biospecimens, to elucidate idiopathic or genetic disease mechanisms.

Proposed creation of model systems, including but not limited to animal models and induced pluripotent stem cells (iPSC), requires strong justification and will not be supported if proposed studies recapitulate currently available resources. Applicants proposing to develop iPSC lines should review NINDS Requirements for Induced Pluripotent Stem Cell Development and Resource Sharing (NOT-NS-14-032) and Notice Announcing the Creation of a Dedicated NINDS Human Cell and Data Repository supporting the Reprogramming, Gene Editing, Banking and Distribution of Fibroblasts and Induced Pluripotent Stem Cells (iPSCs) for Neurological Disorders (NOT-NS-16-003). Applicants are strongly encouraged to use the services of the NINDS Human Cell and Data Repository (NHCDR) for iPSC generation and genome editing (as well as for fibroblasts and peripheral blood mononuclear cells, PBMC).

Letters of Support:

Collaboration with NIH Intramural Researchers (if applicable): Include a letter from the Scientific Director of the collaborating NIH Institute or Center. The letter must describe the role of intramural staff and specify the nature and amount (funding) of NIH intramural resources to be allocated to the proposed project. In addition, the letter should state that the conduct of the project will comply with the DHHS regulations for research involving human subjects (if applicable) and with the PHS policy on vertebrate animal research (if applicable).

NINDS Human Cell and Data Repository (NHCDR): applicants proposing to develop iPSC lines should include a letter of support from the NHCDR, including detailed plan and timeline for related line development and deposit.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

• All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

As Centers of Excellence, Udall Centers are expected to share data, resources and knowledge broadly with the research community. Applicants are expected to detail how this component will:

• Facilitate sharing of knowledge, data, research resources and biospecimens with other Udall Centers and the PD research community as appropriate and consistent with achieving the goals of the program.

Appendix:

Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Basic Research Project)

When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

All instructions in the SF424 (R&R) Application Guide must be followedTranslational Research Project

When preparing your application, use Component Type Project.

In general, translational research applies ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease. The specific goal of the Udall Centers translational research project is to accelerate discoveries leading to early human testing of a new drug, biologic, or other therapeutic or preventative intervention for PD. Successful translational research projects will demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development for the treatment of PD.

Pursuant to the goals of this initiative, Udall Center translational research projects should be directed towards the subsequent pursuit of IND-enabling studies (e.g. through programs sponsored by the NINDS Division of Translational Research, including Cooperative Research to Enable and Advance Translational Enterprises (CREATE) BIO and the NIH Blueprint Neurotherapeutics Network for Small Molecule Development (BPN), and/or by collaboration with industry partners). For example, Udall Center translational research projects could be directed toward the identification of leads (Hit-to-Lead) and optimization of candidate therapeutic leads (Lead Optimization) to move toward future IND-enabling studies or eligibility to enter CREATE and BPN programs at early pre-development stage. Depending upon the scope of the translational research, activities could include demonstration of clear dose-response relationships, in vivo efficacy using clinically relevant outcome measures, in vivo target engagement, in vitro ADME assays, in vitro genotoxicity (Ames test) and cardiotoxicity (hERG activity) assessments, and early in vivo safety read outs (7-day dose range finding in rats). For more examples of complementary drug discovery activities needed to reach IND-enabling studies, refer to BPN PAR-18-546. Only those targeted activities leading to future IND-enabling studies may be included in a translational research project; target identification or mechanistic studies are appropriate for basic research projects only.

Applicants must identify designated translational projects within the application.

Translational Research Projects are focused on use of preclinical model systems. Projects proposing direct involvement of human subjects should be submitted as Clinical Research Projects.

To determine whether a proposed translational research project is responsive to this announcement, applicants are encouraged to contact the Scientific/Research Contact(s) in Section VII, below.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

Complete only the following fields:

• Applicant Information
• Type of Applicant (optional)
• Descriptive Title of Applicant’s Project
• Proposed Project Start/Ending Dates

Enter Human Embryonic Stem Cells in each relevant component.

Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.

Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

Other attachments:

Intellectual Property Strategy: Applications are expected to include an Intellectual property (IP) strategy that is no more than one page. Applicants are encouraged to prepare this section of the application in consultation with their institution's technology transfer officials, if applicable.

A goal of this program is to advance research towards the development of products that will benefit the public. Accordingly, applicants should describe the IP landscape surrounding their therapeutic entity. This should include any known constraints that could impede the development of their therapeutic (e.g., certain restrictions under transfer or sharing agreements, applicants' previous or present IP filings and publications, similar technologies that are under patent and/or on the market, etc.) and how these issues could be addressed as appropriate and consistent with achieving the goals of the program. If the applicant proposes using a technology whose IP is not owned by the applicant's institution, either an investigational therapeutic, FDA-approved therapeutic, or other licensed product, the applicant should address any limitations and move the technology forward consistent with achieving the goals of the program.

If patents pertinent to the therapeutic being developed under this application have been filed, the applicants should indicate the details of filing dates, what types of patents are filed, application status, and associated United States Patent Office (USPTO) links, if applicable. Applicants should also discuss future IP filing plans. For a multiple-PD/PI, multiple-institution application, applicants should describe the infrastructure of each institution for bringing the technologies to practical application and for coordinating these efforts (e.g., licensing, managing IP) among the institutions.

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

• In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Project Lead and provide a valid eRA Commons ID in the Credential field.
• In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
• Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
• If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
• The Translational Research Project Lead must demonstrate excellent scientific productivity and significant potential to advance PD research over the five-year project period. In addition, project leadership requires active, R01-equivalent, independent funding at the time of application submission. The expertise of Project Lead may be in areas outside of PD research, if relevant skills can be readily applied to achievement of Center goals.
• Effort of Translational Research Project personnel must be commensurate with the time required for effective performance of proposed duties.

Budget forms appropriate for the specific component will be included in the application package.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

Specific Aims: State the aims of the translational research project and the therapeutic strategy to be developed. Provide justification as to why the Udall Center structure is required to accomplish the proposed translational project aims.

Research Strategy: Organize the Research Strategy into sections on Significance, Innovation and Approach.

Significance: Describe how proposed translational studies will advance development of novel or improved PD therapeutic entities. Detail how proposed studies address the critical challenge identified by the Center theme. State how, if successful, proposed studies will support further development of candidate therapeutics for the treatment of PD, including steps toward IND-enabling research, e.g. via entry into subsequent translational research programs and/or collaborations with industry partners.

Innovation: Describe novel aspects of the research (e.g. target, method(s), model(s)) and potential to advance state-of-the-art therapeutic strategies for PD.

Approach: Describe proposed therapeutic development activities. Indicate the methodological rigor of proposed studies. Provide the rationale for the chosen model(s) and endpoints, adequacy of controls, route and timing of therapeutic dosing, justification of sample size, statistical methods, blinding methods, strategies for randomization, and robustness and reproducibility of results. Describe how results of the proposed studies will be applied to advance preclinical development, including a plan for continued therapy development that demonstrates an awareness of future goals and challenges. Include preliminary plans to establish the necessary collaborations and funding to further the translational research project.

Responsive translational research studies may include, but are not limited to, the following:

• Target validation, including readouts for target engagement, target activity, and phenotypic results in model biological systems.
• Characterization of candidate therapeutics, including pharmacokinetics, biophysical or physicochemical characteristics, and pharmacodynamic/pharmacokinetic relationship.
• Demonstration of target engagement by the candidate therapeutic.
• Development of pharmacodynamic biomarkers, including those that allow for the direct or downstream readout of target engagement of an intended therapeutic; biomarker studies must comply with policy delineated in NOT-NS-13-020.
• Evaluation of preclinical in vivo efficacy using animal models of PD, particularly in relationship to candidate therapeutic exposure.
• Validation of animal models of PD which include physiologically meaningful endpoints of disease that can be tested in both preclinical and clinical settings.

The following activities are nonresponsive to this FOA; translational research projects containing any of these elements will not be reviewed:

Basic research including target identification and studies of disease mechanism.

Development of preclinical models for the purpose of understanding disease etiology.

Use of tool compounds to identify targets relevant to disease.

IND-enabling studies, such as GLP toxicology, formulation and manufacturing.

Discovery and development of therapeutic devices.

Clinical studies involving non-exempt human subjects research.

The establishment of institutional infrastructure for therapeutic development activities is beyond the scope of this FOA. Applicants will leverage existing institutional or collaborative infrastructure for proposed Udall Center preclinical translational projects.

Letters of Support:

Collaboration with Private Entities (if applicable): A letter of support is expected that addresses any agreement to provide agent(s), any limits on the studies that can be performed with said agent(s), any limitations on sharing of data (including negative results), and whether a licensing agreement(s) is in place. This letter should come from an official within the private entity who has authority to speak on these issues.

Intellectual Property Management (if applicable): A letter of support is expected from the institutional technology transfer official who will be managing intellectual property associated with this project. If research will be performed at more than one institution, include a letter of support from each institution clarifying how intellectual property will be shared or otherwise managed across the institutions.

Collaboration with NIH Intramural Researchers (if applicable): Include a letter from the Scientific Director of the collaborating NIH Institute. The letter must describe the role of intramural staff and specify the nature and amount (funding) of NIH intramural resources to be allocated to the proposed project. In addition, the letter should state that the conduct of the project will comply with the DHHS regulations for research involving human subjects (if applicable) and with the PHS policy on vertebrate animal research (if applicable).

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

• All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

As Centers of Excellence, Udall Centers are expected to share data, resources and knowledge broadly with the research community. Applicants are expected to detail how this component will:

• Facilitate sharing of knowledge, data, research resources and biospecimens with other Udall Centers and the PD research community as appropriate and consistent with achieving the goals of the program.

Appendix:

Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Translational Research Project)

When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

All instructions in the SF424 (R&R) Application Guide must be followed.

When preparing your application, use Component Type Project.'

Udall Center clinical research projects include patient-oriented research, i.e. research that involves direct investigator interaction with human subjects, with a specific focus on understanding the mechanism of human disease.

The NINDS will accept Udall Center applications including clinical studies designed to transiently modify and/or measure a biological process for the purpose of understanding mechanism. These studies are considered clinical trials per NOT-OD-15-015. The NINDS will not accept applications that include clinical trials designed to address safety, tolerability, efficacy and/or effectiveness of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions (e.g., phase I, phase II, phase III, or pivotal clinical trials). Such designs should be submitted to an NINDS clinical trial-specific funding announcement (e.g. PAR-18-420, PAR-18-422).

According to NIH policy, in vitro studies that utilize de-identified samples (i.e. those falling under 45 CFR part 46.101(b) (4) (Exemption 4)) are not considered clinical research. For purposes of this announcement, such studies should be proposed as basic research projects.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

Complete only the following fields:

• Applicant Information
• Type of Applicant (optional)
• Descriptive Title of Applicant’s Project
• Proposed Project Start/Ending Dates

Enter Human Embryonic Stem Cells in each relevant component.

Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.

Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

• In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Project Lead and provide a valid eRA Commons ID in the Credential field.
• In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
• Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
• If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
• The Clinical Research Project Lead must demonstrate excellent scientific productivity and significant potential to advance PD research over the five-year project period. In addition, project leadership requires active, R01-equivalent, independent funding and/or evidence of leadership of a clinical study at the time of application submission. The expertise of the Project Lead may be in areas outside of PD research if relevant skills can be readily applied to achievement of Center goals.
• Effort of Clinical Research Project personnel must be commensurate with the time required for effective performance of proposed duties.

Budget forms appropriate for the specific component will be included in the application package.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

Specific Aims: State the hypothesis and research approaches of the clinical research project. Detail expected contributions to the goals of the Udall Center. Explain why the Udall Center structure is essential to accomplish the proposed aims.

Research Strategy: Organize the Research Strategy into sections on Significance, Innovation and Approach.

Significance: Describe the rationale for proposed clinical studies based on unmet medical need for PD. Describe and clearly justify the identified research need. Address how successful completion of the proposed studies will inform and advance future PD research and clinical trials.

Innovation: Describe novel aspects of clinical studies and potential to inform disease mechanisms and advance state-of-the-art treatment strategies for PD.

Approach: Describe how proposed clinical studies will improve understanding and treatment of PD. State the biological rationale for the intended approach, including supporting data from rigorously designed preclinical experiments and clinical studies. Indicate the methodological rigor of proposed studies. Provide the rationale for the chosen subjects and endpoints, adequacy of controls, justification of sample size, statistical methods, and robustness and reproducibility of results. Areas of investigation may include, but are not limited to, the following examples:

• Improved understanding of prodromal disease and identification of pre-symptomatic PD patients.
• Elucidation of non-motor aspects of Parkinson’s disease, including alterations in mood and cognition, behavioral changes, sleep disturbances, fatigue, autonomic dysfunction, gastrointestinal problems.
• Identification of patient subgroups and at-risk subjects to inform clinical trial design.
• Determination of whether a clinical manipulation produces sufficient evidence of short-term activity, e.g. biomarker activity, target engagement, pharmacokinetic/pharmacodynamic response.
• Development of biomarkers for disease risk, onset, progression, detection, and prevention; biomarkers studies must comply with policy outlined in NOT-NS-13-020.

Proposed Clinical Research projects should be of a mechanistic focus as described above.

Letters of Support:

Collaboration with NIH Intramural Researchers (if applicable): Include a letter from the Scientific Director of the collaborating NIH Institute. The letter must describe the role of intramural staff and specify the nature and amount (funding) of NIH intramural resources to be allocated to the proposed project. In addition, the letter should state that the conduct of the project will comply with the DHHS regulations for research involving human subjects.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide,

• All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

As Centers of Excellence, Udall Centers are expected to share data, resources and knowledge broadly with the research community. Applicants are expected to detail how this component will:

• Expedite timely transfer of information to appropriate, broadly shared databases, including the NINDS Data Management Resource (DMR) or other designated NINDS database, to fulfill data sharing goals as appropriate. Deposition of data solely into an institutional database, whether at the applicant or at a collaborator's institution, may not be considered consistent with achieving the program goals.
• Implement standardized collection and deposition of biospecimens into the designated NINDS biorepository, the Biospecimen Exchange for Neurological Disorders, BioSEND.
• Facilitate sharing of knowledge, data, research resources and biospecimens with other Udall Centers and the PD research community as appropriate and consistent with achieving the goals of the program.

Eligible data and biospecimens from Udall Center clinical research projects are expected to be shared via the NINDS Data Management Resource (DMR) and NINDS BioSEND repository described in "Other Submission Requirements and Information," below, consistent with achieving the goals of the program. For more information regarding consent requirements, see the DMR consent language guidelines. While these guidelines are listed regarding Biomarkers projects, it is expected that all Clinical Research Projects under the Udall Program meet these requirements to promote broad sharing.

Appendix:

Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Clinical Research Project)

When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

All instructions in the SF424 (R&R) Application Guide must be followed.

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

This initiative is not subject to intergovernmental review.

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

For information on how your application will be automatically assembled for review and funding consideration after submission go to: http://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management (SAM). Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

NINDS Research Standardization Practices

All human subjects-focused studies in an NINDS Udall Center will employ a common set of tools and resources that will promote the collection of standardized biospecimens and data across sites. Therefore, applicants should comply with related policies, and relay plans for research standardization of biospecimen collection/distribution/storage, use of Common Data Elements (CDEs) for collection of clinical data, and data collection and storage through the NINDS Data Management Resource (DMR) or other designated NINDS database.

The following information is provided to inform application development as well as prepare successful applicants for Udall Center program activities.

Standardized Biospecimen Collection and Distribution

Biospecimens must be collected using protocols of the NINDS BioSEND Biospecimen Collection, Processing and Shipment Manual and related NINDS PDBP protocols. Biospecimens collected must include whole blood (for DNA and RNA preparation) and serum; collection of peripheral blood mononuclear cells (PBMC) and cerebrospinal fluid (CSF) is encouraged. Deviation from this plan should be discussed and approved by the NINDS program officer. Collection of additional biospecimens (e.g. fibroblasts) should be justified within the application and will require NINDS approval.

Consent forms must clearly state that any biological samples and de-identified clinical data will be appropriately shared with academics or industry and must be consistent with NINDS BioSEND and NINDS PDBP Data Management Resource (DMR) broad consent requirements. A copy of the consent form for each subject should be kept on file by the investigator but does not need to be sent with each sample.

Note that costs for biospecimen collection are not included as a component of the NINDS BioSEND repository award. Therefore, most costs for the biospecimen banking are borne by the grantees utilizing this resource (see NOT-NS-15-046). Applicants planning projects in which biospecimens will be collected are strongly advised to consult with NINDS Biomarkers Repository staff to obtain a quote for biospecimen banking costs (email: biosend@iu.edu).

Standardized Clinical Instruments

Applicants will be required to collect standard NINDS PDBP clinical instruments (including, but not limited to: demographics, medical history, family history, medications) to maximize data harmonization across PD studies. If additional clinical assessments are proposed, the NINDS strongly encourages researchers to use NINDS Common Data Elements (CDEs), including general and PD-specific CDEs. Centers may collect additional clinical information beyond that required by this initiative; those doing so are encouraged to contact the NINDS program official prior to submission. The NINDS PDBP Data Management Resource (details below) has developed web-based forms to assure ease of data entry and quality assurance.

As appropriate, applicants are encouraged to make use of the following resources for clinical research:

NIH Toolbox

Patient-Reported Outcomes Measurement Information System (PROMIS)

Quality of Life in Neurological Disorders (Neuro-QoL)

Clinical Data Management and Storage

Udall Centers will use the NINDS Data Management Resource (DMR) to store biospecimen-related and clinical data collected for Center projects and cores. The DMR provides an essential data coordination tool for the entire PD research community through the development of a web-based data management system that provides tools to NINDS-supported projects for both the collection and quality assurance of data in a standardized format. The DMR also coordinates the assembly of de-identified data into a common database thus enabling the query and distribution of aggregate data for the acceleration of PD research. For NINDS Udall Center projects, patient consent must allow broad sharing of de-identified data and biospecimen resources though the PDBP DMR and the NINDS biomarker and human cell line repositories, respectively, as appropriate.

Application components proposing support for database efforts that are duplicative of DMR functions or responsibilities will be considered nonresponsive.

Activities that are the sole purview of the DMR include: 1) development of standardized electronic data forms, data formats and software for use across multiple cohorts and projects; 2) development of software to support subject scheduling, site tracking, and facilitation and coordination of de-identified clinical and biospecimen data collection across multiple new and existing cohorts and projects through an easy to use web-based entry system for submitters; 3) quality assurance checks of data entry and collection; 4) development of a user-friendly query system for users to evaluate availability of data and biospecimens within and across Udall Centers; 5) development of aggregate data report formats that are user-friendly and supported by well documented data dictionaries; 6) training for both data submitters and data users; 7) coordination of data and biospecimen summary reports and postings in collaboration with NINDS BioSEND; and 8) public outreach for data submission and data use. Development of all electronic data entry forms and quality assurance checks of de-identified data will be performed by the DMR. Center applications will identify key Clinical Core personnel whose responsibility will be to ensure and facilitate data quality, transfer, sharing, and biological specimen submission to the DMR and NINDS BioSEND, respectively. For those studies already utilizing an institutional data management core or resource, successful implementation of a de-identified data transfer plan from the Udall Center to the DMR will be expected, consistent with achieving the goals of the program.

Timely deposition of all de-identified clinical data into the PDBP DMR is expected of the Udall Centers program, consistent with achieving the goals of the program. Clinical data submission into the DMR via ProFoRMS must accompany all biospecimens submitted to the NINDS repository, BioSEND.

Imaging-Based Studies
For applications proposing to include biomedical imaging, including neuroimaging, studies: all formats should be compatible with the Medical Image Processing, Analysis, and Visualization tool (MIPAV).

Studies Ancillary to Parent Studies
Ancillary studies must not interfere with the parent study and must not place undue burden on participants. Approved procedures and policies from the parent study must be followed and must have patient consents that allow broad sharing of de-identified clinical data through the DMR, and deposition of biospecimens in NINDS BioSEND. Review and approval for the use of samples must be completed and a letter of approval must be obtained prior to submission of an application under this FOA.

Subject Consent

Consent forms for Udall Center clinical studies must clearly state that any biological samples and de-identified clinical data will be appropriately shared with academics or industry and must be consistent with the designated NINDS BioSEND and NINDS DMR broad consent requirements.

Induced Pluripotent Stem Cells

Proposed creation induced pluripotent stem cells (iPSC) requires strong justification and will not be supported if proposed studies recapitulate currently available resources, including lines available or pending through the NINDS Human Cell and Data Repository (NHCDR). If development of iPSC lines is proposed, the specific need must be clearly and strongly justified. Applicants proposing to develop isogenic lines should consult the program officer prior to submission. New iPSC lines developed must meet the following criteria: 1) patient consent must allow for broad data and resource sharing (academic and industry investigators) including use for genetic studies, wherein part or all of the genome may be sequenced; 2) the institution/facility must have licenses for iPSC and related (e.g. genome editing, reporter use) technologies that allow deposition and broad distribution of resulting iPSC lines through the NINDS Repository); 3) for iPSC lines currently available through the NINDS repository, gene correction experiments must be done in these lines; 4) a timeline must be provided for banking of available iPSC lines with the NINDS repository; 5) all iPSC lines derived must be characterized for sterility and be free of mycoplasma contamination, have normal karyotypes, normal growth rates and colony morphology, demonstrated pluripotency through a pluritest, scorecard test or equivalent test, demonstrated surface antigen expression of stem cell markers, demonstrated ability to form embryoid bodies and demonstrated transgene silencing for the reprogramming factors used. For gene correction/gene editing projects, investigators will be asked to whole genome sequence the original and edited clones and deposit this data with the NINDS Data Management Resource (DMR).

Leveraging Existing Research Resources

Applicants are strongly encouraged to leverage existing research resources for their studies whenever possible. Such resources may include tissue, cellular, or DNA samples from the NINDS BioSEND repository or other existing biospecimen, imaging and data repositories. The NINDS BioSEND repository receives, processes, stores, and distributes biospecimen resources from NINDS funded studies that can be shared by the neuroscience research community, and currently banks a variety of biospecimens including DNA, plasma, serum, RNA, CSF, and saliva. Leveraging the resources and support from PD advocacy groups, private research foundations, academic institutions, other government agencies and the NIH Intramural program are also encouraged. Studies are also encouraged that leverage the resources of ongoing clinical trials supported through other Federal or private funds.

Collaborations with NIH Intramural Scientists

NIH intramural researchers may serve as collaborators or consultants on Udall Center projects.

During the application process, intramural researchers must provide their Scientific Director with copies of formal letters of collaboration, and in turn obtain written approval from the Scientific Director for inclusion within the Udall Center application. All requests for substantial intramural involvement in extramural research activities must also be approved by the Ethics and Grants Management Offices from the respective NIH Institute or Center (IC).

If selected, appropriate funding will be provided by the NIH Intramural Program. Budget requests by NIH intramural scientists will be limited to the incremental costs required for participation. As such, these requests will not include any salary and related fringe benefits for career, career conditional or other Federal employees (civilian or uniformed service) with permanent appointments under existing position ceilings or any costs related to administrative or facilities support (equivalent to Facilities and Administrative or F&A costs). These costs may include salary for staff to be specifically hired under a temporary appointment for the project, consultant costs, equipment, supplies, travel, and other items typically listed under Other Expenses. Applicants should indicate the number of person-months devoted to the project, even if no funds are requested for salary and fringe benefits. Intellectual property will be managed in accord with established policy of the NIH in compliance with Executive Order 10096, as amended, 45 CFR Part 7; patent rights for inventions developed in NIH facilities are NIH property unless NIH waives its rights.

According to NIH policy, successfully reviewed applications with substantial intramural involvement will be converted to a cooperative agreement mechanism, with related terms and conditions, prior to award of funds.

At an early planning stage, Udall Center applicants intending to collaborate with NIH intramural investigators are encouraged contact the NINDS Scientific/Research personnel, below.

Participation in Annual Udall Center Meetings

Annual meetings of Udall Center Directors are held each autumn in the Bethesda, MD area. The meeting is designed to provide dedicated time during which Center investigators can discuss emergent issues and approaches in the research and treatment of PD. By providing a focused and interactive Agenda, the annual meeting fosters the initiation and continuation of collaborative efforts and resource sharing among the Centers. Meeting planning duties will be shared between the NINDS and the Udall Center Coordinating Committee (UC3).

Participation in Udall Center Coordinating Committee (UC3) Activities

The Center Director will participate in activities of the Udall Center Coordinating Committee (UC3), which promotes collaboration and strengthens cooperation among the network of active Udall Centers. For example, the UC3 functions to:

• Strengthen communication and data sharing among Udall Centers.
• Define and share best practices and resources.
• Identify novel collaborative research opportunities.
• Pursue mechanisms for translation of research findings toward clinical realization.
• Coordinate activities in areas of common interest, including investigator career enhancement and community outreach.
• Facilitate interdisciplinary collaboration in PD research among and beyond the Udall Centers.
• Develop, implement and monitor metrics for the evaluation of program progress.

The UC3 is led by a Chair and an Executive Committee, who work with the NINDS program officer to achieve these goals. The Chair’s term is one year, to start and end at the annual Directors meeting. The UC3 Executive Committee will consist of past, current and rising Chairs, for a total of three years of service per Chair; respective Center grants must be actively funded during term of service. Each Center Director will be expected to participate on the UC3 for the duration of funding of her/his Center. The UC3 will also include two representatives from Non-Governmental Organizations (NGOs). Additional outside members from the research community will be added on an ad hoc basis to address emergent issues within the program. The UC3 will hold regular teleconferences and will meet annually during the Udall Centers meeting. The NINDS program officer should be included as a participant for all meetings and correspondence.

Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

Important Update: See NOT-OD-18-228 for updated review language for due dates on or after January 25, 2019.

Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

The NINDS Udall Centers of Excellence program prioritizes innovative and integrative research with significant potential for discovery, as well as the potential (new applications) or proven capacity (renewal applications) to serve as national leaders in and local resources for PD research.

Accordingly, reviewers will evaluate the significance of the Center theme as well as potential for success based on the collaborative potential and skill set of the investigative team, significance and innovation of research proposed, overall synergy, organizational framework, community outreach, career development and the potential impact of the proposed Udall Center award upon the PD field.

Specific to applications involving clinical trials:

The scope of this FOA includes only those applications that propose human mechanistic studies that meet the NIH definition of a clinical trial and that fall within the NINDS research priorities. Therefore, responsive applications may only include hypothesis-driven mechanistic clinical studies designed to elucidate the pathobiology, pathophysiology, and neuropathology of PD and related synucleinopathies. The goal of such studies is to address basic questions and to interrogate concepts in biology, behavior, and pathophysiology that will provide insight into understanding PD. Such studies may seek to understand a biological or behavioral process, or the mechanism of action of an intervention. Responsive studies are defined as clinical trials but do not seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions.

Accordingly, reviewers will evaluate proposed mechanistic clinical trials within the context of the proposed Udall Center, as well as according to the specific criteria below.

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the Center to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the Center proposed).

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a Center that by its nature is not innovative may be essential to advance a field.

Does the Center address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the Center are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Does the proposed Center identify and address a critical challenge in PD research? Is there strong evidence that the proposed Center will advance research in PD, through both its scientific projects and cores? Will the proposed Center effectively meet the stated goals of the Udall Centers Program, i.e. to rapidly advance an innovative, interdisciplinary, highly impactful research program while serving as a national leader in PD research? Is the use of the Specialized Center (P50) mechanism justified and will the proposed research benefit from the Center structure?

In addition, reviewers will evaluate the overarching Significance of the proposed Udall Center:

Do the stated goals of the proposed Center demonstrate the potential for research discoveries of high significance? Have the investigators described what knowledge and resources will be contributed to the Udall Centers program, and to PD research at the local and national levels?

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI , do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Will the Udall Center Director (PD/PI) provide visionary scientific leadership of the Center? Does the Director have appropriate leadership experience, including leading a large-scale research program, which predicts success of the Center? Is the Director an established leader in scientific research and/or clinical trials with a history of successful funding? Has the Director dedicated an appropriate time commitment to the Center, including leadership of the Administrative Core? If the Director’s primary area of expertise is in an area other than PD research, is it clear that the Director’s skills can be applied in novel ways to the advancement of PD research and treatment?

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

During evaluation of the proposed Center applications, reviewers will consider the level of innovation specifically related to state-of-the-art PD research, including the following:

Does the Center take novel approaches to advancing the stated goals of the proposed Udall Center, i.e., will proposed research advance understanding of PD and development of novel and/or improved therapies? Are the proposed projects likely to make major rather than incremental advances toward this goal?

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the Center? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility, and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

If the Center involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?

Is the Center organized around a clearly articulated central theme? Is the synergistic relationship among the Center components, especially the scientific and collaborative approaches that will ensure thematic coherence of Center research and activities, clearly described? Is there sufficient scientific evidence to support the formation of a new or continuation of an existing Udall Center?

Will successful completion of proposed objectives directly inform the pathology, progression and treatment of PD? Is there evidence that individual Center investigators will function as an effective collaborative team to achieve the goals of the Center? Has the Center demonstrated ability (renewal applications) or does the Center have the capacity (new applications) to mobilize institutional resources and contribute to PD research at a local and national level?

Are there appropriate plans for the Center to collaborate and otherwise contribute to the overall Udall Centers program, through participating in collaborative research and sharing efforts, the Udall Centers Coordinating Committee, the annual Center Directors' meeting, and other program-wide activities?

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

In addition, reviewers will consider the following:

Will the institution provide support for the Center, e.g. by provision of discretionary resources to the Udall Center Director recruitment of scientific talent, funding for pilot projects, assignment of specialized research space, access to/use of resources, and/or by any other means?

Does the applicant institution support a strong research base on PD and/or other neurodegenerative disorders? If the applicant institution houses other large-scale, PD-related research efforts, is there adequate description of the relationship between the proposed Udall Center and those projects, and is potential overlap addressed appropriately?

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for each project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria (as applicable for the project proposed).

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? How will the project contribute to the overall success of the Udall Center? Will the proposed research result in major rather than incremental advances in PD research?

In addition, for applications involving clinical trials:

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?

Investigator(s)

Is the expertise of the research project leader, collaborators, and other researchers well suited to the project? Does the project lead have a productive record of bringing novel and significant projects to fruition as an independent principal investigator? If the investigator does not have current NIH funding, does (s)he have active, independent funding that is the equivalent of an NIH R01 or demonstrated stewardship of a multi-site clinical trial? Is sufficient investigator effort dedicated to the research project and Center activities?

In addition, for applications involving clinical trials:

With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, or technologies? Are the concepts, approaches or methodologies, or technologies novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or technologies proposed?

In addition, for applications involving clinical trials:

Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility, and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

Is the work proposed within the scope of expertise of the PD/PI and other researchers?

If applicable, does the proposed translational project have the potential to lead to the development of a novel or improved therapy? Is the study appropriately structured to demonstrate whether proposed therapeutic agent(s) will have sufficient biological activity to warrant further development? Is the proposed model, including timing of treatment and route of delivery, justified and are appropriate endpoints included? Is the intellectual property landscape clearly described and justified? Will successful completion of proposed studies lead to further IND-enabling research, either via entry into translational programs and/or industry partnerships? Are the applicants aware of goals and challenges, as well as necessary collaborative interactions required, for future therapy development?

If applicable, is the proposed clinical project rationale based upon a sufficiently rigorous body of high quality preclinical or clinical research? Are the conceptual or clinical framework, designed, methods and analyses adequately developed, well-integrated, well-reasoned and appropriate to the aims of the project? Are the subject population and stated endpoints well-justified?

In addition, for applications involving clinical trials:

Study Design

Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed and rigorous preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed measure(s), and duration of the trial, appropriate and well justified?

Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the biological or behavioral effect due to sex/gender and race/ethnicity?

Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

Data Management and Statistical Analysis

Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

In addition, for applications involving clinical trials:

If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?

Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?

If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?

If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?

Reviewers will provide overall numeric scores; individual criterion scores are not provided. The review criteria for the individual cores are provided below.

Administrative Core

Does the Administrative Core Lead/Center Director have appropriate expertise and dedicate sufficient time to administrative activities? If an Associate Director is named, does that person have required expertise to effectively assist the Center Director with scientific and administrative management? Does the Center Administrator have sufficient expertise with NIH policies, practices and fiscal management to provide support for the program?

Is the line of communication clear between the Center Director and Center Administrator? Is there an appropriate plan for establishing and maintaining effective communications and cooperation among Center investigators and with investigators outside the Center? Is the proposed management structure appropriate for scientific administration, coordination of resource generation and utilization, as well as fiscal administration, procurement, property and personnel management, planning and budgeting? Does the Core support the Center's role as a national leader in PD research?

Are there internal and external procedures for monitoring and evaluating the proposed research projects and core facilities/resources? Are there appropriate plans for management of data, animal models and other resources?

Are there appropriate plans for establishing the External Advisory Committee (EAC), and will the EAC contribute to the oversight of Center research projects, and other components? Are there plans to appoint a patient advocate to the EAC?

Does the Facilities and Resources section of the Administrative Core clearly describe Career Enhancement activities, including a mission statement for and overview of planned activities, and are those activities appropriate for the specific scope of the proposed Center? Are proposed activities well-integrated into the theme of the Center? Are career enhancement activities specifically designed for Udall Center investigators, i.e. are activities separate from and do they enhance/build upon existing institutional resources and programs? For renewals, are accomplishments from the prior funding period described?

Are proposed Center outreach activities designed specifically to inform and engage the public regarding research ongoing in the Udall Center, as well as how that research integrates into current advances in PD research? Do Center investigators participate in community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities? Does the Community Outreach attachment outline a clear and appropriate strategy for the organization of an annual, dedicated Udall Center Symposium? Is the Center website established and maintained (renewals), or are plans to do so described (new applications)? If social media outreach is proposed, are related plans clear, timely and well-justified?

Research Core

Is the Research Core essential to advance the scientific aims of at least two proposed research projects? Does the Core address the central theme of the overall program? Will the facilities or services provided by the Core (including procedures, techniques, and quality control) be used effectively? Are the Core Lead and key personnel well-qualified to provide the Core service(s)? Does the Core generate and share resources that support the Center's status as a local resource for and national leader in PD research (renewals) or have the potential to do so (new applications)? For proposed continuation Cores in renewal applications, was the previous Core successful in achieving its stated goals?

Clinical Core

Is the Clinical Core essential for the support of the proposed clinical research project(s)? Does the Core Leader have the appropriate expertise, seniority and dedicated effort to direct the proposed Clinical Core facility? Are there appropriate plans for the rigorous management and quality control of any research data or materials to be obtained from human subjects?

Are plans in place for subject recruitment? Is there a specific and feasible plan for inclusion of diversity in subject recruitment, and is planned enrollment appropriately reflective of the local demographic? Is the proposed subject cohort well-defined and appropriately diverse? Are proposed plans for recruitment and retention of the population innovative? Is planned enrollment justified and specific to Udall Center research projects? Is the related timeline for the clinical cohort included and appropriate? For competing renewal applications: is there justification for continuation of and/or changes in the Center cohort?

Have standard operating procedures been established for collection and storage of biological samples and/or for genotype/phenotype information? Will annual biospecimen collection adhere to protocols of the NINDS PD Biomarkers Program (PDBP)? Is the annual deposition of biospecimens in the NINDS BioSEND repository addressed? Will clinical data be collected annually using the NINDS PDBP clinical assessments? Will any additional clinical information be collected using NINDS Common Data Elements (CDEs)? Do plans include standardized collection and timely transmission of data to the designated NINDS Data Management Resource (DMR)?

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Study Timeline

Specific to applications involving clinical trials:

Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Not Applicable.

For Renewals, the committee will consider the progress made in the last funding period as the potential for continued excellence in PD research.

Has the Center been productive and generated high-impact research discoveries during the prior funding period? Has the Center remained on the cutting edge of PD research, and does the Center have the infrastructure and team assembled to pursue the proposed objectives? Is there evidence that the Center has served and will continue to serve effectively as a local resource and national leader in PD research?

Not Applicable.

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Not Applicable.

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genomic Data Sharing Plan .

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), convened by the National Institute of Neurological Disorders and Stroke (NINDS), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

• May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
• Will receive a written critique.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the appropriate National Advisory Neurological Disorders and Stroke (NANDS) Council. The following will be considered in making funding decisions:

• Scientific and technical merit of the proposed project as determined by scientific peer review.
• Availability of funds.
• Relevance of the proposed project to program priorities.
• Areas of complementarity to existing Udall Centers.
• Compliance with data and resource sharing policies.
• Only one NINDS Morris K. Udall Center of Excellence may be awarded at any one institution).
• Consideration of NINDS programmatic priorities may also include relevance of proposed studies to research priorities identified during the NINDS PD2014 strategic planning effort.

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain applicable clinical trials on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/.

Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that the application as well as all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols. Data and Safety

Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).

Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

Awardee-selected projects that involve clinical trials or studies involving greater than minimal risk to human subjects require prior approval by NIH prior to initiation.

• The awardee institution will provide NIH with written study protocols that address risks and protections for human subjects in accordance with NIH s Instructions for Preparing the Human Subjects Section of the Research Plan.
• The awardee institution will provide NIH with specific plans for data and safety monitoring, and will notify the IRB and NIH of serious adverse events and unanticipated problems, consistent with NIH DSMP policies.

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

Not Applicable

When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 Award Term and Conditions for Recipient Integrity and Performance Matters.

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten on-time submission, and post-submission issues)

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application processes and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

Beth-Anne Sieber, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
Email: sieberb@ninds.nih.gov

Chief, Scientific Review Branch
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9223
Email: nindsreview.nih.gov@mail.nih.gov

Tijuanna DeCoster, PhD, MPA
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9231
Email: decostert@ninds.nih.gov

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.